Skip to contentR
Revolution Medicines, Inc.
R
RVMDWRevolution Medicines, Inc. Q1 2024 · 10-Q
Revenue$0.00$0.00no prior Q1 2023 on file Net Income-$116.00M-$116.00Mno prior Q1 2023 on file EPS Diluted-$0.70-$0.70no prior Q1 2023 on file Operating Income-$140,859,000— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
Free Cash Flowderived-$163,727,000— ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end